TR200000957T2 - Hiperglisemi tedavisinde tiazolidinedion kullanımı - Google Patents
Hiperglisemi tedavisinde tiazolidinedion kullanımıInfo
- Publication number
- TR200000957T2 TR200000957T2 TR2000/00957T TR200000957T TR200000957T2 TR 200000957 T2 TR200000957 T2 TR 200000957T2 TR 2000/00957 T TR2000/00957 T TR 2000/00957T TR 200000957 T TR200000957 T TR 200000957T TR 200000957 T2 TR200000957 T2 TR 200000957T2
- Authority
- TR
- Turkey
- Prior art keywords
- hyperglycemia
- thiazolidinedione
- treatment
- mammal
- toxic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Plazma glükoz seviyelerinin 126mg/dI ila 140 mg/dI, arasinda oldugu hiperglisemi için tedavisi için, ihtiyaci olan bir memeliye etkili bir toksik olmayan ve farmasötik olarak kabul edilebilir miktarlarda bir ensülin sensitizörü uygulanmasini içeren bir yöntem.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9721692.3A GB9721692D0 (en) | 1997-10-13 | 1997-10-13 | Novel treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200000957T2 true TR200000957T2 (tr) | 2000-08-21 |
Family
ID=10820481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2000/00957T TR200000957T2 (tr) | 1997-10-13 | 1998-10-12 | Hiperglisemi tedavisinde tiazolidinedion kullanımı |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1023057A1 (tr) |
JP (1) | JP2001519383A (tr) |
KR (1) | KR20010024482A (tr) |
CN (1) | CN1281358A (tr) |
AP (1) | AP1223A (tr) |
AU (1) | AU9547198A (tr) |
BG (1) | BG104405A (tr) |
BR (1) | BR9815220A (tr) |
CA (1) | CA2305289A1 (tr) |
CZ (1) | CZ20001298A3 (tr) |
EA (1) | EA200000418A1 (tr) |
GB (1) | GB9721692D0 (tr) |
HR (1) | HRP20000256A2 (tr) |
HU (1) | HUP0003673A3 (tr) |
ID (1) | ID24439A (tr) |
IL (1) | IL135515A0 (tr) |
NO (1) | NO20001897L (tr) |
OA (1) | OA11519A (tr) |
PL (1) | PL339804A1 (tr) |
SK (1) | SK5322000A3 (tr) |
TR (1) | TR200000957T2 (tr) |
UA (1) | UA66809C2 (tr) |
WO (1) | WO1999018944A1 (tr) |
YU (1) | YU28700A (tr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL140664A0 (en) * | 1998-07-21 | 2002-02-10 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing apoptosis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
-
1997
- 1997-10-13 GB GBGB9721692.3A patent/GB9721692D0/en not_active Ceased
-
1998
- 1998-10-12 WO PCT/GB1998/003067 patent/WO1999018944A1/en not_active Application Discontinuation
- 1998-10-12 UA UA2000042049A patent/UA66809C2/uk unknown
- 1998-10-12 IL IL13551598A patent/IL135515A0/xx unknown
- 1998-10-12 KR KR1020007003935A patent/KR20010024482A/ko not_active Application Discontinuation
- 1998-10-12 HU HU0003673A patent/HUP0003673A3/hu unknown
- 1998-10-12 OA OA1200000107A patent/OA11519A/en unknown
- 1998-10-12 ID IDW20000670A patent/ID24439A/id unknown
- 1998-10-12 PL PL98339804A patent/PL339804A1/xx unknown
- 1998-10-12 CN CN98812016A patent/CN1281358A/zh active Pending
- 1998-10-12 CZ CZ20001298A patent/CZ20001298A3/cs unknown
- 1998-10-12 BR BR9815220-3A patent/BR9815220A/pt not_active Application Discontinuation
- 1998-10-12 TR TR2000/00957T patent/TR200000957T2/tr unknown
- 1998-10-12 AU AU95471/98A patent/AU9547198A/en not_active Abandoned
- 1998-10-12 EA EA200000418A patent/EA200000418A1/ru unknown
- 1998-10-12 AP APAP/P/2000/001788A patent/AP1223A/en active
- 1998-10-12 JP JP2000515579A patent/JP2001519383A/ja active Pending
- 1998-10-12 SK SK532-2000A patent/SK5322000A3/sk unknown
- 1998-10-12 YU YU28700A patent/YU28700A/sh unknown
- 1998-10-12 EP EP98949088A patent/EP1023057A1/en not_active Withdrawn
- 1998-10-12 CA CA002305289A patent/CA2305289A1/en not_active Abandoned
-
2000
- 2000-04-12 NO NO20001897A patent/NO20001897L/no not_active Application Discontinuation
- 2000-05-02 HR HR20000256A patent/HRP20000256A2/hr not_active Application Discontinuation
- 2000-05-05 BG BG104405A patent/BG104405A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SK5322000A3 (en) | 2000-09-12 |
CZ20001298A3 (cs) | 2001-08-15 |
GB9721692D0 (en) | 1997-12-10 |
UA66809C2 (uk) | 2004-06-15 |
IL135515A0 (en) | 2001-05-20 |
WO1999018944A1 (en) | 1999-04-22 |
OA11519A (en) | 2004-02-09 |
ID24439A (id) | 2000-07-20 |
HUP0003673A3 (en) | 2001-12-28 |
CN1281358A (zh) | 2001-01-24 |
CA2305289A1 (en) | 1999-04-22 |
AP2000001788A0 (en) | 2000-06-30 |
YU28700A (sh) | 2003-10-31 |
BG104405A (en) | 2000-12-29 |
KR20010024482A (ko) | 2001-03-26 |
EP1023057A1 (en) | 2000-08-02 |
NO20001897L (no) | 2000-06-09 |
PL339804A1 (en) | 2001-01-02 |
HRP20000256A2 (en) | 2000-12-31 |
HUP0003673A2 (hu) | 2001-10-28 |
NO20001897D0 (no) | 2000-04-12 |
AP1223A (en) | 2003-11-13 |
JP2001519383A (ja) | 2001-10-23 |
EA200000418A1 (ru) | 2000-10-30 |
BR9815220A (pt) | 2000-11-14 |
AU9547198A (en) | 1999-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200101089A1 (ru) | Новый способ лечения | |
GR3034508T3 (en) | Use of insulin sensitizing agents to treat hypertension. | |
CY1105254T1 (el) | Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο | |
SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
LU91928I2 (fr) | Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®) | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
TR199902033T2 (tr) | Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari. | |
MXPA03003870A (es) | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. | |
TR200101174T2 (tr) | Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid. | |
NO20083276L (no) | Behandling av diabetes med tiazolidindion og sulfonylurea | |
TR200000957T2 (tr) | Hiperglisemi tedavisinde tiazolidinedion kullanımı | |
AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
TR200000135T2 (tr) | Tiazolidinedion ve sülfonilüre ile diabet tedavisi. | |
TR200101336T2 (tr) | Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar | |
BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase | |
NO20005223L (no) | Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen | |
TR200000958T2 (tr) | Hiperglisemi tedavisinde tiazolidinedion kullanımı. | |
TR199801133T2 (tr) | Tip II diyabetin tedavisi veya önlenmesi için nitrik oksit (NO) sentaz inhibitörü | |
WO2001047509A3 (en) | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions | |
MX9701529A (es) | Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos. |